Filing Flows › Avalo Therapeutics (AVTX) › Q4 2024 › vs Q4 2023
Avalo Therapeutics (AVTX) Q4 2024 vs Q4 2023 (year over year)
Avalo Therapeutics's revenue fell $379K (-66%) from $571K in Q4 2023 to $192K in Q4 2024.
Avalo Therapeutics, Q4 2024: revenue $192K (-66% year over year), net loss $35.3M, operating cash flow −$15.0M. The chart draws each line against Q4 2023, the increases inside each band.
Every line
| Line | Q4 2024 | Q4 2023 | Change | % |
|---|---|---|---|---|
| Revenue | $192K | $571K | −$379K | -66% |
| Net loss | $35.3M | $8.2M | $27.2M | +333% |
| Costs & expenses | $35.5M | $8.7M | $26.8M | +306% |
| Operating costs | $13.5M | $8.2M | $5.3M | +64% |
| Interest & other, net | $21.9M | $519K | $21.4M | 42× |
| Income tax | $114K | −$9K | $123K | — |
| Research & development | $8.2M | $1.9M | $6.3M | +338% |
| Other operating costs | $87K | $3.7M | −$3.6M | -98% |
| Operating cash sources | $35.3M | $8.2M | $27.2M | +333% |
| Depreciation & amortization | $68K | $43K | $25K | +58% |
| Share-based compensation | $2.9M | $776K | $2.1M | +274% |
| Working capital & other | $17.3M | $4.6M | $12.7M | +278% |
| Cash used in operations | $15.0M | $2.8M | $12.3M | +444% |
| Net loss absorbed | $35.3M | $8.2M | $27.2M | +333% |
Questions
How much did Avalo Therapeutics's revenue grow year over year in Q4 2024?
Avalo Therapeutics's revenue fell $379K (-66%) from $571K in Q4 2023 to $192K in Q4 2024.